Bavarian Nordic: Covid-19 vaccine beats Pfizer's on several parameters
New studies will further explore tentative yet promising data on Bavarian Nordic and Adaptvac's Covid-19 vaccine candidates at a larger scale. According to Bavarian Nordic VP Investor Relations & Communications, the company still hopes to receive economic aid from Danish authorities.
BY RITZAU FINANS, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Moods are bright at Bavarian Nordic after data from the first human trials of the company's Covid-19 vaccine candidate, ABNCoV2, confirm that Bavarian is holding a well-tolerated inoculation, showing higher antibody levels than approved vaccines from firms like Pfizer and partner Biontech, says Bavarian Nordic Vice President of Investor Relations & Communications Rolf Sass Sørensen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
